Skip to main content
Premium Trial:

Request an Annual Quote

Fred McLafferty, Carol Robinson, Forest White, Alan Marshall, Robert Monaghan, Lawrence Cohen, William Emhiser

Premium

Fred McLafferty, professor emeritus at Cornell University, received the 2003 American Society for Mass Spectrometry Award for a Distinguished Contribution in Mass Spectrometry at this week’s annual ASMS conference in Montreal (see p. 6). The award honors his contribution to the mechanistic definition of the 6-membered ring hydrogen rearrangement in the gas-phase ion chemistry of carbonyl compounds, known as the “McLafferty Rearrangement.”

 

Carol Robinson, professor in the department of chemistry at Cambridge University, England, received the Biemann Medal this week at the annual ASMS conference in Montreal. She won the award for her achievements and contributions to the areas of protein mass spectrometry and structural biology, presenters said.

 

Forest White, senior research scientist at MDS Proteomics in Charlottesville, Va., will leave the com- pany on July 1 to become assistant professor in the biological engineering department at the Massachusetts Institute of Technology. White holds a PhD in analytical chemistry from Florida State University, where he studied with Alan Marshall.

 

Robert Monaghan has become CEO of Hayward, Calif.-based Zyomyx (see p. 1). He replaces Lawrence Cohen, who is now the company’s vice chairman. Monaghan has also joined Zyomyx’s board of directors. Most recently, he was president of Sigma Diagnostics and its subsidiaries. Prior to that, he was a vice president at Dade Behring. He also served as vice president for sales at Behring Diagnostics. Monaghan holds an MBA in marketing from California State University, San Bernardino, and a BS in business administration from Arizona State University.

 

William Emhiser has become president of North American operations at Sydney, Australia-based Proteome Systems. He joins the company from Millipore, where he was president of the life science division. Previously, he was president of Amicon, which was acquired by Millipore in 1996. Prior to that, he was president and chief operating officer of Gelman Sciences, which is now part of Pall.

 

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.